Synonym
Vodobatinib; K-0706; K0706; K0706;
IUPAC/Chemical Name
2-chloro-6-methyl-N'-{4-methyl-3-[(quinolin-3-yl)ethynyl]benzoyl}benzohydrazide
InChi Key
ZQOBVMHBVWNVBG-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H20ClN3O2/c1-17-10-12-22(26(32)30-31-27(33)25-18(2)6-5-8-23(25)28)15-20(17)13-11-19-14-21-7-3-4-9-24(21)29-16-19/h3-10,12,14-16H,1-2H3,(H,30,32)(H,31,33)
SMILES Code
CC1=C(C=C(C(NNC(C2=C(Cl)C=CC=C2C)=O)=O)C=C1)C#CC(C=N3)=CC4=C3C=CC=C4
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
|
Solvent |
mg/mL |
mM |
| Solubility |
| Soluble in DMSO |
0.0 |
100.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
453.93
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Li YC, Lin BH, Murakami M, Wu YS, Hung TH, Chen CC, Ambudkar SV, Wu CP.
Vodobatinib overcomes cancer multidrug resistance by attenuating the drug efflux
function of ABCB1 and ABCG2. Eur J Pharmacol. 2024 Dec 24;988:177231. doi:
10.1016/j.ejphar.2024.177231. Epub ahead of print. PMID: 39725134.
2: Walsh RR, Damle NK, Mandhane S, Piccoli SP, Talluri RS, Love D, Yao SL,
Ramanathan V, Hurko O. Plasma and cerebrospinal fluid pharmacokinetics of
vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment
of Parkinson's disease. Parkinsonism Relat Disord. 2023 Mar;108:105281. doi:
10.1016/j.parkreldis.2023.105281. Epub 2023 Jan 14. PMID: 36717298.
3: Khan SA, Khan S, Kausar H, Shah R, Luitel A, Gautam S, Parajuli SB, Rauniyar
VK, Khan MAB. Insights into the management of Lewy body dementia: a scoping
review. Ann Med Surg (Lond). 2024 Jan 3;86(2):930-942. doi:
10.1097/MS9.0000000000001664. PMID: 38333295; PMCID: PMC10849442.
4: Scalzulli E, Carmosino I, Bisegna ML, Martelli M, Breccia M. CML Resistant to
2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions. Curr Hematol
Malig Rep. 2022 Dec;17(6):198-205. doi: 10.1007/s11899-022-00683-3. Epub 2022
Oct 20. PMID: 36264428.
5: Scalzulli E, Carmosino I, Costa A, Bisegna ML, Martelli M, Breccia M.
Management of Chronic Myeloid Leukemia Patients in Later Lines: The Role of
Ponatinib and New Compounds. Clin Lymphoma Myeloma Leuk. 2023 Jun;23(6):420-425.
doi: 10.1016/j.clml.2023.03.004. Epub 2023 Mar 20. PMID: 37029061.
6: Malik S, Hassan S, Eşkazan AE. Novel BCR-ABL1 tyrosine kinase
inhibitors in the treatment of chronic myeloid leukemia. Expert Rev Hematol.
2021 Nov;14(11):975-978. doi: 10.1080/17474086.2021.1990034. Epub 2021 Oct 20.
PMID: 34608829.
7: WHO Drug Information, Vol. 34, No. 2, 2020
